Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Palbociclib Capsules, 75 mg, 100 mg, and 125 mg. The company has enclosed its press release regarding the above subject matter on 09 November 2020.
The above information is a part of company’s filings submitted to BSE.